Beschreibung
Carbamazepine significantly reduces venlafaxine plasma concentrations through CYP3A4 induction, potentially reducing antidepressant efficacy.
Mechanismus
Carbamazepine induces CYP3A4 and CYP2C19, which are involved in venlafaxine metabolism, accelerating its clearance and reducing plasma levels.
Klinische Bedeutung
Sub-therapeutic venlafaxine levels may lead to depression relapse or inadequate pain control in patients using it for neuropathic pain.
Maßnahmen
Monitor clinical response; venlafaxine dose increase may be required; consider an antidepressant less affected by CYP3A4 induction.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.